Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$6.0 million.

  • Arcus Biosciences' Gains from Investment Securities fell 50000.0% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year increase of 2142.86%. This contributed to the annual value of -$22.0 million for FY2024, which is 25714.29% down from last year.
  • Per Arcus Biosciences' latest filing, its Gains from Investment Securities stood at -$6.0 million for Q3 2025, which was down 50000.0% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Gains from Investment Securities registered a high of $11.0 million during Q3 2023, and its lowest value of -$10.0 million during Q2 2022.
  • For the 5-year period, Arcus Biosciences' Gains from Investment Securities averaged around -$388888.9, with its median value being -$343500.0 (2021).
  • Data for Arcus Biosciences' Gains from Investment Securities shows a peak YoY increase of 1121111.11% (in 2022) and a maximum YoY decrease of 235098.04% (in 2022) over the last 5 years.
  • Over the past 5 years, Arcus Biosciences' Gains from Investment Securities (Quarter) stood at $3.8 million in 2021, then tumbled by 126.67% to -$1.0 million in 2022, then soared by 300.0% to $2.0 million in 2023, then plummeted by 400.0% to -$6.0 million in 2024, then changed by 0.0% to -$6.0 million in 2025.
  • Its Gains from Investment Securities stands at -$6.0 million for Q3 2025, versus $1.0 million for Q2 2025 and -$6.0 million for Q4 2024.